Press release
Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GSK
Discover the latest drugs and treatment options in the Renal Cell Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Renal Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
* July 2024:- Hospital das Clinicas de Ribeirao Preto- CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer. The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
* July 2024;- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
* DelveInsight's Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
* The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
* Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Stay ahead with the most recent pipeline outlook for Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Renal Cell Carcinoma Treatment [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cell Carcinoma Emerging Drugs Profile
* CM082: Betta Pharmaceuticals
CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.
* TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.
* IPI-549: Infinity Pharmaceuticals
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.
* CMN-001: ColImmune
Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.
Explore groundbreaking therapies and clinical trials in the Renal Cell Carcinoma Pipeline. Access DelveInsight's detailed report now! @ New Renal Cell Carcinoma Drugs [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Subcutaneous
* Intravenous
* Intramuscular
* Molecule Type
Renal Cell Carcinoma Products have been categorized under various Molecule types such as
* Bispecific Antibody
* Peptides
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Renal Cell Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Renal Cell Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Renal Cell Carcinoma Pipeline Report
* Coverage- Global
* Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
* Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
* Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Renal Cell Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Renal Cell Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Renal Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Renal Cell Carcinoma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Renal Cell Carcinoma Collaboration Deals
* Late Stage Products (Phase III)
* TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IPI-549: Infinity Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AVB-S6-500: Aravive Inc.
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Renal Cell Carcinoma Key Companies
* Renal Cell Carcinoma Key Products
* Renal Cell Carcinoma - Unmet Needs
* Renal Cell Carcinoma - Market Drivers and Barriers
* Renal Cell Carcinoma - Future Perspectives and Conclusion
* Renal Cell Carcinoma Analyst Views
* Renal Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=renal-cell-carcinoma-pipeline-2024-astrazeneca-infinity-pharmaceuticals-ipsen-novartis-aveao-pharmaceuticals-merck-sharp-dohme-corp-pfizer-bayer-healthcare-incyte-corporation-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GSK here
News-ID: 3571078 • Views: …
More Releases from ABNewswire
Marketing Expert Tony Hayes Reveals Why 97% of Ad Campaigns Fail in First 8 Seco …
Digital marketing strategist Tony Hayes releases comprehensive guide exposing hidden campaign settings that drain advertising budgets. New newsletter edition includes 15 proven fixes with implementation checklists for businesses struggling with low-converting paid traffic.
CHON BURI, THAILAND - February 12, 2026 - Tony Hayes, digital marketing strategist and entrepreneur, has released a comprehensive breakdown of the 15 most common-yet invisible-mistakes destroying advertising campaign profitability. The latest edition of his newsletter, "Stop Burning…
LiTime Appears at GCSAA 2026: Empowering Golf Cart Power Upgrades with Systemati …
LiTime showcased its GC Smart golf cart lithium lineup and a One-Stop Power System-batteries,waterproof chargers,and monitoring display -advancing outdoor power system.
NEW YORK - As a global pioneer in lithium battery technology, LiTime [https://www.litime.com/pages/all-products?utm_source=NEWS&utm_medium=PR&utm_campaign=LT-GCSAAshow-0216]appeared at the GCSAA Conference & Trade Show 2026 held in Orlando, United States, from February 4 to 5. The exhibition is one of the most influential annual industry events in the field of golf course management and…
CabinetsDoors Delivers Installer-Friendly Custom Cabinet Doors Backed by Family- …
As a family-operated extension of Urban Fresh Services, CabinetsDoors.net [http://cabinetsdoors.net] combines manufacturing precision with practical installation knowledge. This dual perspective allows the company to design, cut, and ship cabinet doors that are not only dimensionally accurate but also installer-friendly in real-world applications.
Unlike large, impersonal mass-production facilities, CabinetsDoors.net was built from the ground up by professionals who have worked directly in kitchens, bathrooms, and renovation projects for years. That hands-on background…
Yasam Ayavefe Introduces Global Investment Portfolio and Hospitality Hub
[https://www.yasamayavefe.io/about/]Founder of the Mileo chain of hotels - Yasam Ayavefe
A new information platform has been introduced to make it easier for partners, investors, and journalists to track the work of Yasam Ayavefe [https://www.yasamayavefe.io/] across investments and hospitality, without relying on scattered references or secondhand summaries. His launch reflects a simple idea markets often overlook: trust strengthens when the facts are easy to find, easy to verify, and easy to keep…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
